-
1.发明申请公开(公告)号：US20160346312A1
公开(公告)日：2016-12-01
申请号：US15162535
申请日：2016-05-23
IPC分类号： A61K31/713 , A61K9/00 , A61K45/06
CPC分类号： A61K31/713 , A61K9/0073 , A61K31/7125 , A61K45/06
摘要： The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
摘要翻译： 本公开涉及通过肺内施用多核苷酸Toll样受体9激动剂治疗癌症的方法。 本公开的方法适用于治疗肺的原发性癌症，以及肺转移性癌症及其额外的肺癌。 另外，本公开提供具有适于肺内给药的免疫刺激和毒性特征的多核苷酸Toll样受体9激动剂。
-
公开(公告)号：US20160003807A1
公开(公告)日：2016-01-07
申请号：US14694919
申请日：2015-04-23
IPC分类号： G01N33/50 , C07K14/705 , C12N5/0789
CPC分类号： G01N33/5073 , A01K67/0271 , A01K67/0278 , A01K2217/052 , A01K2227/105 , A01K2267/0387 , C07K14/705 , C07K14/70596 , C12N5/0647 , C12N2510/00 , G01N33/502 , G01N33/5023 , G01N33/5038
摘要： Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.
摘要翻译： 本文提供了表达转基因动物的人Toll样受体8（TLR8）及其使用方法。
-
公开(公告)号：US20210196819A1
公开(公告)日：2021-07-01
申请号：US17000149
申请日：2020-08-21
发明人： Ying YU , Andrew Evan DENKER , Svetlana SADEKOVA , Uyen Truong PHAN , Robert A. KASTELEIN , David Ross KAUFMAN , Robert L. COFFMAN , Cristiana GUIDUCCI , Robert S. JANSSEN
IPC分类号： A61K39/395 , A61K45/06 , A61K31/7115 , C07K14/435 , A61K39/39 , C07K16/28 , C07K16/24 , A61P35/00
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
-
4.发明申请公开(公告)号：US20180264023A1
公开(公告)日：2018-09-20
申请号：US15989055
申请日：2018-05-24
IPC分类号： A61K31/713 , A61K31/7125 , A61K9/00 , A61K45/06
CPC分类号： A61K31/713 , A61K9/0073 , A61K31/7125 , A61K45/06
摘要： The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
-
公开(公告)号：US20180169229A1
公开(公告)日：2018-06-21
申请号：US15577369
申请日：2016-05-26
申请人： Ying YU , Andrew Evan DENKER , Svetlana SADEKOVA , Uyen truong PHAN , Robert A. KASTELEIN , David Ross KAUFMAN , Robert L. COFFMAN , Cristiana GUIDUCCI , Robert S. JANSSEN , MERCK SHARP & DOHME CORP. , DYNAVAX TECHNOLOGIES CORPORATION
发明人： Ying YU , Andrew Evan DENKER , Svetlana SADEKOVA , Uyen Truong PHAN , Robert A. KASTELEIN , David Ross KAUFMAN , Robert L. COFFMAN , Cristiana GUIDUCCI , Robert S. JANSSEN
IPC分类号： A61K39/395 , A61K31/7115 , A61K45/06 , C07K14/435 , A61P35/00
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
-
6.发明申请公开(公告)号：US20170326232A1
公开(公告)日：2017-11-16
申请号：US15488353
申请日：2017-04-14
IPC分类号： A61K39/395 , A61K31/7088 , C12N15/113 , C12Q1/68
CPC分类号： A61K39/395 , A61K9/0019 , A61K9/143 , A61K31/7088 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/54 , A61K2039/55505 , A61K2039/55555 , A61K2039/55561 , A61K2039/64 , C12N15/1135 , C12Q1/6886
摘要： The present disclosure relates to methods for treating cancer by intratumoral delivery of particles containing a Toll-like receptor 9 agonist (TLR9) and a tumor antigen, in which the TLR9 agonist is a polynucleotide or a chimeric compound thereof. The methods of the present disclosure involve injection of the particles into at least one tumor, and are effective for treating both injected and uninjected tumors of a mammalian subject. Additionally, the present disclosure provides immunogenic compositions containing the particles, as well as methods of manufacture thereof.
-
公开(公告)号：US20190151345A1
公开(公告)日：2019-05-23
申请号：US16141828
申请日：2018-09-25
IPC分类号： A61K31/713 , A61K31/7125 , A61K45/06 , A61K9/00
CPC分类号： A61K31/713 , A61K9/0073 , A61K31/7125 , A61K45/06
摘要： The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
-
8.发明申请公开(公告)号：US20180161427A1
公开(公告)日：2018-06-14
申请号：US15577377
申请日：2016-05-26
申请人： Ying YU , Elliot Keith CHARTASH , Svetlana SADEKOVA , Uyen Truong PHAN , Robert A. KASTELEIN , Robert L. COFFMAN , Cristiana GUIDUCCI , Robert S. JANSSEN , MERCK SHARP & DOHME CORP. , DYNAVAX TECHNOLOGIES CORPORATION
发明人： Ying YU , Elliot Keith CHARTASH , Svetlana SADEKOVA , Uyen Truong PHAN , Robert A. KASTELEIN , Robert L. COFFMAN , Cristiana GUIDUCCI , Robert S. JANSSEN
IPC分类号： A61K39/395 , A61K31/7125 , A61P35/00
CPC分类号： A61K39/3955 , A61K31/7125 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2039/55561 , A61P35/00 , C07K16/244
摘要： The present disclosure describes combination therapies comprising an anti-IL-10 antibody or antigen-binding fragment thereof and a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
-
9.发明申请METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY 有权用于抑制免疫反应和自身免疫的方法和组合物公开(公告)号：US20150275216A1
公开(公告)日：2015-10-01
申请号：US14613280
申请日：2015-02-03
IPC分类号： C12N15/117 , A61K45/06 , A61K31/7125 , A61K31/7115 , A61K31/712 , A61K31/713 , A61K31/711
CPC分类号： C12N15/117 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K45/06 , C12N2310/17 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/331 , C12N2310/3341 , C12N2310/336 , C12N2310/345 , C12N2310/3521
摘要： The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response.
摘要翻译： 本申请涉及免疫调节多核苷酸和/或免疫调节化合物与其它治疗剂组合的用途。 本申请还涉及包含修饰的免疫调节序列的免疫调节多核苷酸和/或免疫调节化合物。 它还涉及免疫调节多核苷酸和/或免疫调节化合物的施用，其包含修饰的免疫调节序列以调节免疫应答。
-
公开(公告)号：US20150203850A1
公开(公告)日：2015-07-23
申请号：US14553857
申请日：2014-11-25
IPC分类号： C12N15/117
CPC分类号： C12N15/117 , A61K31/573 , A61K31/7125 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2320/30 , C12N2320/31 , Y02A50/411 , C12N2310/3521
摘要： The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
摘要翻译： 本申请涉及调节包含TLR7和/或TLR9抑制剂的免疫应答的组合物和方法，例如免疫调节多核苷酸和/或免疫调节化合物。 本申请还涉及用于预测和/或确定疾病对包括TLR7和/或TLR9抑制剂的治疗反应性的组合物和方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.024 秒)
